Terminated PHASE2 INTERVENTIONAL 1-arm NCT01719861

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

Sponsor: Joel Neal

Conditions Neuroendocrine Tumors Small Cell Lung Cancer (SCLC)

Interventions Desipramine HCL

Updated 8 times since 2017 Last updated: Mar 2, 2017 Started: Oct 31, 2012 Primary completion: May 31, 2014 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of efficacy

Other Neuroendocrine Tumors trials with similar outcome

NCT00985946 · Phase PHASE2 · Apr 2015

Browse all Neuroendocrine Tumors trials

This PHASE2 trial investigates Neuroendocrine Tumors and Small Cell Lung Cancer (SCLC) and is currently terminated or withdrawn. Joel Neal leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2017 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Joel Neal

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States